Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.

Prakash Raj Oli,Dhan Bahadur Shrestha,Jurgen Shtembari,Pratik Gyawali,Laxmi Regmi,Amit Bhandari,Swati Dhungel,Jishanth Mattumpuram,Kailash Pant,Sudhir Mungee

Coronary artery disease（2023）

引用 0|浏览2

暂无评分

摘要

Based on this meta-analysis, bivalirudin plus a post-PCI high-dose infusion-based anticoagulation during STEMI PCI has significant benefits over heparin therapy for cardiovascular outcomes without a significant increase in the risk of thrombotic outcomes.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要